Cover Image
市場調查報告書

高雪氏症的全球市場:2015-2019年

Global Gaucher Disease Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 326307
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
高雪氏症的全球市場:2015-2019年 Global Gaucher Disease Market 2015-2019
出版日期: 2015年03月18日 內容資訊: 英文 88 Pages
簡介

全球高雪氏症市場預計從2014年到2019年以7.60%的年複合成長率成長。

本報告提供全球高雪氏症的市場相關調查、高雪氏症概要、分類、診斷法、管理法、主要藥物與開發平台狀況、各治療方法、分子類型、投藥途徑、投藥形態、地區的市場規模的變化與預測、市場成長的各種影響因素分析、競爭環境與主要企業的市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 關於疾病
    • 分類
    • 症狀
    • 診斷
  • 病因
  • 流行病學
  • 臨床病理
  • 管理
    • 酵素補充療法
    • 基材合成阻礙療法
  • 病患的負擔

第7章 開發平台環境

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 各治療法市場

  • 酵素補充療法
  • 基材合成阻礙療法

第10章 各分子類型市場

  • 生技藥品
  • 小分子

第11章 各投藥途徑市場

  • 口服
  • 非口服

第12章 各劑型市場

  • 固體
  • 液體

第13章 各地區市場

第14章 購買標準

第15章 推動市場成長要素

第16章 成長推動因素與其影響

第17章 市場課題

第18章 成長推動因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Genzyme
    • Shire
    • Actelion Pharmaceuticals
    • Pfizer
  • 其他卓越供應商

第22章 主要供應商分析

  • Actelion Pharmaceuticals
  • Genzyme
  • Pfizer
  • Shire
    • 主要資料
    • 產業概要
    • 各產業收益
    • 各地區收益
    • 產業策略
    • 主要的發展趨勢
    • SWOT分析等

第23章 相關報告

圖表

目錄
Product Code: IRTNTR5483

About Gaucher Disease

Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities.

TechNavio's analysts forecast the Global Gaucher Disease market to grow at a CAGR of 7.60 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Gaucher Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes:

  • Enzyme replacement therapy
  • Substrate reduction therapy

Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments:

  • Biologics
  • Small Molecules

Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments:

  • Oral
  • Parenteral

Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments:

  • Solid
  • Liquid

TechNavio's report, Global Gaucher Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gaucher Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actelion Pharmaceuticals
  • Genzyme
  • Pfizer
  • Shire

Other Prominent Vendors

  • Amicus Therapeutics
  • Belrose Pharma
  • Bionaturis
  • Biosidus
  • ISU Abxis
  • JCR Pharmaceuticals
  • LIXTE Biotechnology
  • Neuraltus Pharmaceuticals
  • Protalix BioTherapeutics
  • Teva Pharmaceuticals
  • UCB
  • Utrecht Holdings
  • Zywie

Market Driver

  • Special Provisions for Orphan Drugs
  • For a full, detailed list, view our report

Market Challenge

  • Limited Patient Population
  • For a full, detailed list, view our report

Market Trend

  • Regulatory Assistance in Emerging Nations
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
    • 06.1.1. Types of Gaucher Disease
    • 06.1.2. Symptoms
    • 06.1.3. Diagnosis
  • 06.2. Etiology
  • 06.3. Epidemiology
  • 06.4. Clinical Manifestations
  • 06.5. Management
    • 06.5.1. Enzyme Replacement Therapy
    • 06.5.2. Substrate Reduction Therapy
  • 06.6. Economic Burden

07. Pipeline Analysis

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Type of Therapy

  • 09.1. Enzyme Replacement Therapy
  • 09.2. Substrate Reduction Therapy

10. Market Segmentation by Type of Molecule

  • 10.1. Biologics
  • 10.2. Small Molecules

11. Market Segmentation by Route of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Market Segmentation by Dosage Form

  • 12.1. Solid
  • 12.2. Liquid

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Genzyme
    • 21.2.2. Shire
    • 21.2.3. Actelion Pharmaceuticals
    • 21.2.4. Pfizer
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Actelion Pharmaceuticals
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Geographical Segmentation 2013
    • 22.1.4. Business Strategy
    • 22.1.5. Recent Developments
    • 22.1.6. SWOT Analysis
  • 22.2. Genzyme
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Product Segmentation by Revenue 2013
    • 22.2.4. Product Segmentation by Revenue 2012 and 2013
    • 22.2.5. Geographical Segmentation
    • 22.2.6. Business Strategy
    • 22.2.7. Recent Developments
    • 22.2.8. SWOT Analysis
  • 22.3. Pfizer
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Geographical Segmentation by Revenue
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis
  • 22.4. Shire
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Geographical Segmentation by Revenue 2013
    • 22.4.4. Business Strategy
    • 22.4.5. Recent Developments
    • 22.4.6. SWOT Analysis

23. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of Gaucher Disease
  • Exhibit 3: Types of Gaucher Disease
  • Exhibit 4: Heredogram of Inheritance Pattern for Gaucher Disease
  • Exhibit 5: Clinical Manifestations of Gaucher Disease
  • Exhibit 6: Snapshot of Economic Burden of Gaucher Disease
  • Exhibit 7: Clinical Trials by Status (as of February 2015)
  • Exhibit 8: Clinical Trials by Phase (as of February 2015)
  • Exhibit 9: Snapshot of Global Gaucher Disease Market 2014
  • Exhibit 10: Global Gaucher Disease Market 2014-2019 (US$ million)
  • Exhibit 11: Drivers and Challenges of Global Gaucher Disease Market
  • Exhibit 12: Segmentation of Global Gaucher Disease Market by Type of Therapy
  • Exhibit 13: Segmentation of Global Gaucher Disease Market by Type of Therapy 2014
  • Exhibit 14: Segmentation of Global Gaucher Disease Market by Type of Molecule
  • Exhibit 15: Segmentation of Global Gaucher Disease Market by Type of Molecule 2014
  • Exhibit 16: Segmentation of Global Gaucher Disease Market by Route of Administration
  • Exhibit 17: Segmentation of Global Gaucher Disease Market by Route of Administration 2014
  • Exhibit 18: Segmentation of Global Gaucher Disease Market by Dosage Form
  • Exhibit 19: Segmentation of Global Gaucher Disease Market by Dosage Form 2014
  • Exhibit 20: Segmentation of Global Gaucher Disease Market by Geography 2014
  • Exhibit 21: Global Gaucher Disease Market Share Analysis 2014
  • Exhibit 22: Genzyme: Product Portfolio
  • Exhibit 23: Cerezyme: SWOT Analysis
  • Exhibit 24: Cerdelga: SWOT Analysis
  • Exhibit 25: Shire: Product Portfolio
  • Exhibit 26: Vpriv: SWOT Analysis
  • Exhibit 27: Actelion Pharmaceuticals: Product Portfolio
  • Exhibit 28: Zavesca: SWOT Analysis
  • Exhibit 29: Pfizer: Product Portfolio
  • Exhibit 30: Elelyso: SWOT Analysis
  • Exhibit 31: Actelion Pharmaceuticals: Geographical Segmentation by Revenue 2013
  • Exhibit 32: Genzyme: Product Segmentation by Revenue 2013
  • Exhibit 33: Genzyme: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 34: Genzyme: Geographical Segmentation
  • Exhibit 35: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 36: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 37: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 38: Shire: Geographical Segmentation by Revenue 2013
Back to Top